Mainstreaming Reproductive Genetic Innovation
Four potential avenues for structuring a societal discourse on reproductive genetic innovation in the U.S.

Four potential avenues for structuring a societal discourse on reproductive genetic innovation in the U.S.

The consequences that result from state bans and restrictions on medication abortion represent just one example of “healthcare federalism.”

“Drugs and the FDA” is a must-read for anyone interested in how the FDA became the trusted regulatory agency it is today.

Once sponsors decide to capture/share expanded access-derived data above and beyond that needed, what should IRBs do?

The Supreme Court seems poised to say that the existence of a secular medical exemption to vaccine mandates means a state must offer a religious exemption.

In some cases there may be value in collecting “real world data” from Expanded Access.

While it may not seem controversial to promote honesty before the USPTO, a recent Federal Register Notice goes far beyond requiring candor.

Expanded access allows patients who lack other treatment options to try unapproved medical products in development.

How should the FDA regulate recreational drugs, if it has the power to do so?
